YS Biopharma Co. Statistics
Total Valuation
YS has a market cap or net worth of $136.61 million. The enterprise value is $182.95 million.
| Market Cap | 136.61M |
| Enterprise Value | 182.95M |
Important Dates
The last earnings date was Friday, April 19, 2024, before market open.
| Earnings Date | Apr 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
YS has 188.33 million shares outstanding. The number of shares has increased by 50.62% in one year.
| Shares Outstanding | 188.33M |
| Shares Change (YoY) | +50.62% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 81.43% |
| Owned by Institutions (%) | 4.98% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 0.18 |
| PB Ratio | 2.08 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 1.18.
| Current Ratio | 0.94 |
| Quick Ratio | 0.71 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 754 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.46% in the last 52 weeks. The beta is 0.55, so YS's price volatility has been lower than the market average.
| Beta (1Y) | 0.55 |
| 52-Week Price Change | -59.46% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 46.22 |
| Average Volume (30 Days) | 231,427 |
Short Selling Information
The latest short interest is 96,845, so 0.05% of the outstanding shares have been sold short.
| Short Interest | 96,845 |
| Short Previous Month | 116,756 |
| Short % of Shares Out | 0.05% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Pretax Income | n/a |
| Net Income | n/a |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -$0.56 |
Balance Sheet
The company has $30.75 million in cash and $77.09 million in debt, giving a net cash position of -$46.34 million or -$0.25 per share.
| Cash & Cash Equivalents | 30.75M |
| Total Debt | 77.09M |
| Net Cash | -46.34M |
| Net Cash Per Share | -$0.25 |
| Equity / Book Value | 65.54M |
| Book Value Per Share | 0.35 |
| Working Capital | -7.77M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
YS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.62% |
| Shareholder Yield | -50.62% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for YS is $5.25, which is 623.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.25 |
| Price Target Difference | 623.74% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | -5.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |